Abstract Library

#1900 Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors

Introduction: Well-differentiated G1/G2 pancreatic NET (pNET) may evolve towards well-differentiated G3 pNET or carcinoma (pNEC)

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Olivia H

Authors: Hentic O, Cros J, Rebours V, Zappa M, Muller N,

Keywords: dedifferentiation, new biopsy,

#1557 Dual High Throughput Proteomic and Transcriptomic Screen for Predictive Biomarkers of Everolimus Sensitivity in Pancreatic NET

Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: CROS J

Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,

Keywords: PNET, everolimus, predictive biomarkers,

#1546 O6-Methylguanine DNA Methyltransferase (MGMT) Expression by Immunochemistry May Help Predict Response to Streptozotocin-based Chemotherapy in Pancreatic Neuroendocrine Tumours

Introduction: Streptozotocin (STZ) is an alkylating agent inducing DNA damage mainly repaired by MGMT. STZ-based chemotherapy is the first line treatment of non-resectable well-differentiated PNET. As for temozolomide, tumour MGMT deficiency may predict the efficacy of STZ in PNET.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Hentic O

Authors: Hentic O, Cros J, Zappa M, Rebours V, Muller N,

Keywords: MGMT, Streptozotocin, PFS ,

#1124 Correlation Between the 18F-FDG Uptake and Pathological Data in Well-Differentiated Digestive and Pulmonary Neuroendocrine Tumors (NET)

Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Bucau M, Laurent-Bellue A, Cros J, Hentic O, Rebours V,

Keywords: Neuroendocrine tumors, PET-scan, 18-FDG, Ki67, VHL, metabolism,

#898 Evaluation of Tumor Response to Targeted Therapies in Precision-Cut Slices of Human Pancreatic Neuroendocrine Tumors

Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Bucau M, Cros J, Rebours V, Albuquerque M, Paradis V,

Keywords: pancreas, targeted therapies, tissue culture, neuroendocrine tumors,